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Background: We investigated gender differences in treatment outcome during first line antiretroviral treatment
(ART) in a hospital setting in Tanzania, assessing clinical, social demographic, virological and immunological factors.
Methods: We conducted a cohort study involving HIV infected patients scheduled to start ART and followed up to
1 year on ART. Structured questionnaires and patients file review were used to collect information and blood was
collected for CD4 and viral load testing. Gender differences were assessed using Kruskal-Wallis test and chi-square
test for continuous and categorical data respectively. Survival distributions for male and female patients were
estimated using the Kaplan-Meier method and compared using Cox proportional hazards models.
Results: Of 234 patients recruited in this study, 70% were females. At baseline, women had significantly lower
education level; lower monthly income, lower knowledge on ARV, less advanced HIV disease (33% women; 47%
men started ART at WHO stage IV, p = 0.04), higher CD4 cell count (median 149 for women, 102 for men, p = 0.02)
and higher BMI (p = 0.002). After 1 year of standard ART, a higher proportion of females survived although this was
not significant, a significantly higher proportion of females had undetectable plasma viral load (69% women, 45%
men, p = 0.003), however females ended at a comparable CD4 cell count (median CD4, 312 women; 321 men)
signifying a worse CD4 cell increase (p = 0.05), even though they still had a higher BMI (p = 0.02). The unadjusted
relative hazard for death for men compared to women was 1.94. After correcting for confounding factors, the Cox
proportional hazards showed no significant difference in the survival rate (relative hazard 1.02).
Conclusion: We observed women were starting treatment at a less advanced disease stage, but they had a lower
socioeconomical status. After one year, both men and women had similar clinical and immunological conditions. It
is not clear why women lose their immunological advantage over men despite a better virological treatment
response. We recommend continuous follow up of this and more cohorts of patients to better understand the
underlying causes for these differences and whether this will translate also in longer term differences.* Correspondence: fausta_mosha@yahoo.com
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The widespread use of combination Antiretroviral
Therapy (ART) has improved the lives of people living
with HIV through reducing morbidity and mortality
[1]. An infectious disease with an almost universally
fatal outcome has been transformed into a manageable
chronic infectious disease. Due to this, HIV testing ser-
vices have expanded rapidly in many developing coun-
tries including Tanzania in order to reach ambitious
targets for ART coverage [2]. However, in a substantial
proportion of patients the effectiveness of ART is not
sufficient with as consequence virological, clinical and
immunological decay [3].
Currently, in resource limited settings, physicians start
antiretroviral therapy based on the appearance of symp-
toms, CD4 + T-cell count and the progression of loss of
CD4+ T-cells [4]. However, the success of ART in HIV
infection may be influenced by numerous other factors.
There is limited data presenting a combined assessment
of the parameters that may affect treatment outcome in
routine clinical management of HIV-infected patients in
resource limited settings. It has been reported that a
delay of starting ART to WHO clinical stage IV [5] or
BMI below 16 kg/m2 is associated with a significantly
higher mortality after starting treatment [6]. Within a
setting of comparable clinical care, survival from the
point of diagnosis of AIDS is associated mostly with the
WHO stage at AIDS diagnosis, but differences in age,
gender, race, and risk behaviour also exert an influence
on survival [7].
The progression rates to AIDS and clinical manifesta-
tions of diseases associated with HIV infection might
differ between women and men because of biological
and socioeconomic factors [8]. Previous investigations
found different rates of HIV disease progression and of
virological and immunological response to antiretroviral
therapy among HIV-infected women compared with
men [9,10]. Some evidence suggests that HIV positive
men have worse treatment outcomes than their women
counterparts in Africa [11]. The observed differences
may also be due to differences in access to ARV. In sev-
eral countries, access to care and treatment is an import-
ant issue for HIV infected women, most of whom
belong to ethnic or racial minorities. Males appear not
to access HIV services as often as their female counter-
parts and also have worse treatment outcomes, including
mortality. The proportion of males enrolled in ART pro-
grams in Africa is lower than females [11]. Other studies
found that, women may also be less likely to start ART
because they have less time to keep HIV outpatient
appointments because of family commitments, fears
about pregnancy, or socioeconomic circumstances [12].
In resource-limited settings, men are more likely to
have more advanced disease at HIV diagnosis, which isthought to put them at higher risk of adverse outcomes
and less likely to respond well to ART. Some studies
found that women had higher CD4 cell count at ART ini-
tiation than men [9]. In several large HIV outcome stud-
ies from both developed countries and resource-limited
settings, base-line clinical and immunologic status has
been found to be a significant predictor of HIV-related
morbidity and mortality. Men have also been found to
have a significantly higher rate of loss to follow-up and
non adherence to ART, with one study showing a direct
correlation with HIV outcomes in Tanzania [13]. The
clinical course in HIV infected women and men also dif-
fer because of hormones and age at the time of HIV ac-
quisition [14]. Biologic differences between men and
women have been suggested as shaping immunologic
responses to ART and mortality risk.
Tanzania is among the countries where ART is cur-
rently been scaled up [2]. The main concern is whether
the costly treatment programs translate to effective re-
duction in morbidity and mortality among patients start-
ing ART. To date, however, to our knowledge, no
studies have addressed potential gender differences in
access to combination therapy and subsequent short-
term prognosis in Tanzania. With growing demand for
ARV drugs in Tanzania, the effect of other factors on
disease progression is an important question.
Based on this we conducted a study to examine the
gender difference in the disease progression and out-
comes among HIV patients on ART attending a Care
and Treatment Centre (CTC) in Dar es Salaam Tanzania
from 2010 to 2011.
Methods
Setting
The study was conducted at the CTC in Temeke Munici-
pal Hospital of Dar es Salaam region. Temeke is one of
the three administrative districts of Dar es Salaam region,
with an area of 656 square kilometres and is the largest
district with a population of 927,310 (growth rate of 4.3%
per year) [15]. Since 2005, the Centre has provided com-
prehensive care for almost 10,398 HIV-infected indivi-
duals. On average, 90 patients were initiated ART every
month, when the CD4 counts were below 200 cells/μl or
between 200–350 cells/μl when categorized with HIV de-
fining WHO stage III or IV diseases [4].
Study design
We conducted a cohort study in which we followed up
HIV-infected ARV naïve patients for one year. All patients
who were HIV positive, above 18 years of age, ARV naïve
but were due to start ART were enrolled in this study upon
receipt of their informed consent. We excluded patients
whose medical records for the previous year could not be
obtained in the clinic. Patient enrolment was done for
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was calculated using OpenEpi with the following assump-
tions, 95% significance level, 80% power, female to male
ratio of 2.7:1 [16] 7.6% of men progressing to AIDS after
1 year and relative risk of 2.7 [16]. The obtained minimum
sample size was 229; 67 males and 162 females.
Data collection
A structured questionnaire translated in Swahili was used
to collect all the detailed information on social demo-
graphic variables and anthropometrics information. Data
with respect to HIV diagnosis, clinical and ARV treatment
was collected from the patient record files and the CTC
database. Patients were categorized according to the clin-
ical and performance scale of the staging system for
patients infected with HIV-1 proposed by WHO [5]. The
differences on these variables were assessed between males
and females. All patients were followed for a period of one
year after starting standard treatment as per Tanzania
guidelines [4] where treatment outcome was evaluated
after 12 months from the time of initiation of therapy.
Ethical clearance
Ethical clearance to conduct the study was obtained
from the National Institute for Medical Research in
Tanzania and permission to conduct the study was
granted by the Hospital authority. Written Informed
consent was obtained from all study participants by
signing the provided consent form. Patient identifying
information was de-linked from the collected data.
Laboratory testing
Blood was collected from all the participants in EDTA
collection tubes, CD4 level was estimated using Becton
Dickinson FACSCalibur, and viral load using TaqMan
Viral-Load Assay COBASW AmpliPrep at the National
Health Laboratory in Tanzania.
Data analysis
Data were analyzed using Epi Info version 3.5.1 and
STATA 11. Gender differences were assessed using the
Kruskal-Wallis test for continuous variables and the chi-
square test for categorical data. Descriptive analysis was
done for the basic demographic, clinical and immuno-
logical characteristics of patients as well as continuous
variables like CD4 counts, age, plasma viral load levels
and BMI for both males and females. The criterion for
significance for all analyses was a two-sided p-value of
less than 0.05. Survival distributions for male and female
patients were estimated using the Kaplan-Meier method.
Patients who were lost to follow up were censored at the
date when they were last seen. Patients who were still
alive at the date when the study ended were censored at
this date. Survival times were expressed in days. Cox’sproportional hazards regression models were used to as-
sess the associations between patient characteristics and
outcomes. All other variables were included in multivari-
able models to assess their impact on the association be-
tween gender and outcomes.
Results
Social demographic characteristics
A total of 234 patients were recruited in this study, 164
(70%) females and 70 (30%) males with a refusal rate of
6% and 25% respectively. Not all patients eligible to start
ART were enrolled in this study because not all met the
inclusion criteria. Significantly more males attended sec-
ondary schools than females; had a higher income and a
better knowledge on ARV use (Table 1). There was no
significant difference in median age (36 years), alcohol
intake, use of traditional medicine and history of use of
intravenous drug of abuse (Table 1).
Clinical characteristics and history at start of ART
Significantly more males tested for HIV following a chronic
illness, in contrast with females who tested without signs
of AIDS. Consequently, the disease stage at HIV diagnosis
was significantly more advanced in men, more men had
CD4 count < 100 cells/ml at baseline, they had a signifi-
cantly lower Body Mass Index and higher mean Log10
viral load (males 5.5; females 5.1) (Table 1). Most patients
(79%) had been recently diagnosed (< 1 year); however the
time period between HIV diagnoses to initiation of therapy
was not significantly different (Table 1).
Treatment response and disease progression
All the patients were receiving triple therapy combin-
ation of any of the five drugs Zidovudine, Lamivudine,
Stavudine, Efavirenz and Nevirapine. There was no sig-
nificant difference on the treatment regimen between
men and women. The prevalence of adherence to ART
as measured by consistence in keeping appointment was
not different between females (62.8%) and males (62.9%)
(Table 2). After one year of treatment with ART, the
virological response was significantly better in females
than in males (females 69%; males 45% with undetect-
able viral load) but the mean CD4 increase was sig-
nificantly higher in males (230 cells/ml) than females
(202 cells/ml) (Table 3). The BMI was still signifi-
cantly higher in females (24.5) compared to males
(22.5), but the percentage increase was not significantly
different. Also, more females (61.6%) survived than
males (50%) with more deaths occurring in males; how-
ever the difference was again not significant. The un-
adjusted relative hazard for death for males at 1 year of
ART was 1.94 with a confidence interval of 0.91 to
4.11, p = 0.08 (Figure 1). Cox proportional hazards (of a
model containing social demographic and clinical
Table 1 Baseline characteristics of 234 HIV-1 infected naïve patients, Dar es Salaam, 2010
Characteristics Females (N = 164) Males (N = 70) P Value
Categorical Variables N (%) N (%)
Primary level education 156 (95.1) 59 (84.3) 0.005
Above 100 US Dollar monthly income 57 (34.8) 43 (61.4) 0.0002
Having relative to remind to take medication 133 (81.1) 59 (84.3) 0.95
Alcohol Intake 33 (20.1) 18 (25.7) 0.4
Use of traditional medicine 97 (59.2) 45 (65.2) 0.5
History of Intravenous Drug abuse 8 (4.9) 7 (10) 0.2
Knowledge on ARV use and side effects 10 (6.9) 14 (20) 0.005
HIV testing due to Chronic illness 105 (64) 55 (78.6) 0.04
Starting treatment within one year of HIV diagnosis 130 (79.3) 55 (78.6) 0.96
Presence of 2 or more opportunistic infections 75 (45.7) 37 (52.9) 0.3
WHO Staging at initiation of therapy
Stage I 16 (9.8) 5 (7.1) 0.6
Stage II 49 (29.9) 16 (22.9) 0.3
Stage III 82 (50.0) 34 (48.6) 0.8
Stage IV 17 (10.4) 15 (21.4) 0.04
CD4 < 100 cells/μl at ART initiation 50 (33.3)* 31 (47.0)* 0.05
Continuous variables Median (IQR) Median (IQR) P Value
Age (Years) 35 (30.5-43.5) 37 (33.5-42.0) 0.38
CD4 (cells/μl) at ART initiation 149 (6-148; 75-218) 102 (3-221; 47-184) 0.02
Continuous Variables Mean (SD) Mean (SD) P Value
BMI at initiation of therapy 22 (5) 20 (4) 0.002
Log10 Viral Load (RNA copies/ml) at initiation of therapy 5.1 (1.3) 5.5 (1.1) 0.05
Legend:
*Data missing for females [14 (8.5%)] and males [4 (5.7%)].
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rate after 1 year on treatment between male and females
(relative hazard 1.02, 95% CI 0.75, 1.38). The reported op-
portunistic infections during one year of follow up were
not significantly different: mainly fever (40%), skin and hair
conditions (42%), tuberculosis (15%), diarrhoea (15%) and
Herpes Zoster (14%), (Figure 2).
Discussion
Our analysis of gender difference found significant clin-
ical and social-demographic variations between femalesTable 2 One year Outcomes of 234 HIV infected patients
after starting ART from September 2010 to August 2011
Characteristics Females (N = 164) Males (N = 70) P Value
N (%) N (%)
Death 21 (12.8) 14 (20) 0.2
Alive 101 (61.6) 35 (50.0) 0.1
Lost to follow up 42 (25.6) 21 (30.0) 0.5
Missed appointments 103 (62.8) 44 (62.9) 0.99and males. Similar as in other studies, males were
reporting for care with a more advanced disease than
females. Sex differences in health seeking behaviour are
known to exist as indicated in several studies [17]. This
can be attributed, in part; due to the fact that females
are having extra entry points to HIV services e.g.
through PMTCT services, however this was not the case
in this study, where the majority of the patients were
tested after a long term illness. The most common rea-
son for HIV testing was AIDS related syndrome, more
than voluntary testing, and this was more pronounced in
males, denying the patients time for care at CTC prior
to ART.
While there was a difference in disease stage at regis-
tration for care at CTC, both genders were presenting
late and there was not much difference on the period of
illness before starting ART between the two groups.
Males however were better informed about the use of
ARVs than females. For both males and females, late
presenting resulted in a median CD4 at initiation of
therapy below 150 cells/ml, where in ideal situation the
majority of patients on follow up will start ART with a
Table 3 Progression of patients one year on ART, Dar es Salaam
Characteristics Females (N = 101) Males (N = 53) P Value
Percentage with undetectable viral load 70 (69%) 24 (45%) 0.003
Continuous variables Median (IQR) Median (IQR)
CD4 (cells/μl) count after 1 year 312 (252-413) 321 (110-480) 0.6
Continuous Variables Mean (SD) Mean (SD)
Percentage BMI increase (from Baseline) 10.5 (14.2) 9.8 (17.5) 0.3
BMI after 1 year 24.5 (4.8) 22.5 (4.1) 0.02
Percentage weight gain 10.4 (14.3) 9.3 (17.3) 0.2
CD4 (cells/μl) increase from baseline 202 (516; 35-163) 230 (272; 86-181) 0.05
Mosha et al. BMC Public Health 2013, 13:38 Page 5 of 7
http://www.biomedcentral.com/1471-2458/13/38higher CD4 count and a less advanced disease. Starting
ART with low CD4 counts has been shown to be asso-
ciated with early mortality mainly caused by immune
Reconstitution Inflammatory Syndrome (IRIS), which
appears after starting ART at advanced HIV disease
(WHO stage IV), CD4 count below 50 cells/ul and BMI
below 16 kg/m2 [4] which could also have happened to
some of the patients in this cohort. Another study has
indicated that a low CD4 cell count at ART initiation
was a strong predictor of mortality [18] and this could
be the case in our study.
Despite the facts that all the patients were prepared to
start ART, there were still a significant proportion of
patients who were using traditional medicine, alcohol
and injection drug abuse. The history of using traditional
medicine and alcohol was high among our study partici-
pants, particularly among males. This may also be a rea-
son of delaying medical treatment until late at WHO
stage III and stage IV when the patients had already
developed opportunistic infections. Injection drug use
(IDU) is also associated with both, non-adherence to













Figure 1 Kaplan-Meier Survival Curves on Time to Death, for 234 patunstable housing, have undiagnosed mental illness, high
rates of incarceration, and street-involved survival-life-
styles, which may all complicate delivery of HIV-related
treatments [19].
Overall, females were found to start ART at a less
advanced disease stage, with higher CD4 count and
higher BMI, and with lower viral loads than males.
Similar findings are reported by other studies [9]. Given
the high proportion of drug abuse and alcohol in our
study, our patients may have been predisposed to poor
adherence [20]. There was no significant difference on
ART adherence as measured by consistency on keeping
appointments, but it was indeed low in both groups.
Drug and alcohol consumption may also influence sur-
vival of HIV-infected individuals by exacerbating im-
munosuppression, enhancing the toxicity of ARV on
liver cells and accelerating liver damage and may de-
press the immune system leading to increased multipli-
cation of the virus in mononuclear cells [21]. After one
year of treatment, immune recovery was good in both
males and females; however, despite the better start for





ients, Dar es Salaam.
Figure 2 Observed Opportunistic infection during one year of follow up, Dar es Salaam Tanzania.
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though a higher proportion of males died (not statisti-
cally significant), the males who survived were found to
have significantly higher mean CD4 increase than
females, despite a better virological treatment response
in women. This is in contrast with the findings of other
studies which found better survival, less disease pro-
gression and better immunological recovery among
females on HAART [10,16,22]. The difference could be
due to a shorter follow up (one year) in our study, a
bias among the high proportion of patients lost to
follow-up or true differences in our setting. The fact
that men recovered quickly during ART, despite their
late presentation is encouraging. It is however unclear
why the women in our study lost their advantage so
quickly, which is in contrast with other studies. It may
be related to the fact that they are less educated with
lower monthly income, as it has been found through
other studies in Tanzania [13].
The differences that we found will need further
evaluation as this may need redefining the time to ini-
tiate ART in the two groups and the methods to
monitor treatment response. The possibility of initiat-
ing ART at lower viral loads in women, especially dur-
ing the early stages of infection, merits further study.
Although the relative viral load has a similar predictive
value for progression to AIDS for men and women,
the same absolute viral load seems to confer different
risks for AIDS between the sexes [17]. Because mani-
festations of HIV infection stem from the interplay be-
tween viral and host factors, sex differences in
immune modulation will likely play instrumental roles
in determining the course of disease. Both groups
reported opportunistic infections; but more fever and
oral candidiasis was reported by females than males,
however, the difference was not statistically significant.
Because of the late presentation to CTC, care andtreatment services like prophylaxis against opportunis-
tic infections may be suboptimal.
Our study findings are limited by the following issues:
our cohort was rather small and may not necessarily
represent all HIV-infected patients in need of treatment.
We also missed some of the clinical information that
may be useful on comparing the differences between
females and males HIV patients. Due to the high num-
ber of Lost to follow-up (LTF), mortality is likely
underestimated.
Conclusion
We assessed the gender differences on HIV disease pro-
gression and outcomes after one year of ART among
HIV infected patients and whether this potential differ-
ence is influenced by socio-demographic, clinical, im-
munological and virological differences among patients
starting ART in a hospital in Dar es Salaam. Male HIV
patients delay seeking treatment and enter into treat-
ment at a significantly more advanced stage of HIV in-
fection, which predisposes them to increased mortality
and worse treatment outcome. However, we observed
that after one year of ART, males and females had simi-
lar clinical and immunological conditions. It is not clear
why women lose their immunological advantage over
men already at 1 year of treatment despite a better viro-
logical treatment response. It may be related to the study
design, to the fact that women had a lower socio-
economical status or to biological differences. We rec-
ommend continuous follow up of this and more cohort
of patients to understand responses to ART and the dif-
ferences between males and females, together with advo-
cating early HIV diagnosis and treatment.
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